Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.
Article Details
- CitationCopy to clipboard
Waterson AG, Stevens KL, Reno MJ, Zhang YM, Boros EE, Bouvier F, Rastagar A, Uehling DE, Dickerson SH, Reep B, McDonald OB, Wood ER, Rusnak DW, Alligood KJ, Rudolph SK
Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.
Bioorg Med Chem Lett. 2006 May 1;16(9):2419-22. Epub 2006 Feb 17.
- PubMed ID
- 16483772 [ View in PubMed]
- Abstract
Anilinoalkynylpyrimidines were prepared and evaluated as dual EGFR/ErbB2 kinase inhibitors. A preference was found for substituted phenyl and heteroaromatic rings attached to the alkyne. In addition, the presence of a potential hydrogen bond donor appended to this ring was favored. Selected molecules in the series demonstrated some activity against human tumor cell lines.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Lapatinib Epidermal growth factor receptor IC 50 (nM) 10 N/A N/A Details Lapatinib Receptor tyrosine-protein kinase erbB-2 IC 50 (nM) 9 N/A N/A Details